Transformation to acute leukemia is a major complication of myeloproliferative neoplasms (MPNs), however, the genetic changes leading to transformation remain largely unknown. We screened nine patients with post-MPN leukemia for chromosomal aberrations using microarray karyotyping. Deletions on the short arm of chromosome 7 (del7p) emerged as a recurrent defect. We mapped the common deleted region to the IKZF1 gene, which encodes the transcription factor Ikaros. We further examined the frequency of IKZF1 deletions in a total of 29 post-MPN leukemia and 526 MPN patients without transformation and observed a strong association of IKZF1 deletions with post-MPN leukemia in two independent cohorts. Patients with IKZF1 loss showed complex karyotypes, and del7p was a late event in the genetic evolution of the MPN clone. IKZF1 deletions were observed in both undifferentiated and differentiated myeloid cell types, indicating that IKZF1 loss does not cause differentiation arrest but rather renders progenitors susceptible to transformation, most likely through chromosomal instability. Induced Ikzf1 haploinsufficiency in primary murine progenitors resulted in elevated Stat5 phosphorylation and increased cytokine-dependent growth, suggesting that reduced expression of IKZF1 is sufficient to perturb growth regulation. Thus, IKZF1 loss is an important step in the leukemic transformation of a subpopulation of MPN patients.
Introduction
Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic disorders, including three major disease entities: polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). Although the characteristics of PV and ET are excessive production of red blood cells and platelets, respectively, the main feature of PMF is replacement of the bone marrow by fibrotic tissue. 1 In spite of the diversity of MPN phenotypes, there are several features shared by all three disease entities including specific clinical complications and clonal hematopoiesis, which is triggered by the somatic mutation of an individual hematopoietic stem cell. 2 A number of oncogenic somatic mutations have been identified, most prominently a gain-of-function mutation of the Janus Kinase 2 (Jak2) gene (JAK2-V617F), present in more than half of all MPN patients. [3] [4] [5] [6] In spite of the dominant role of JAK2-V617F in MPN, other mutations with lower frequencies have been identified, such as activating mutations in exon12 of JAK2 7, 8 and in MPL. 9, 10 Lossof-function mutations were recently also found in the CBL 11 and TET2 genes. 12 In addition, a variety of chromosomal deletions and acquired uniparental disomies have been observed in MPN, highlighting the genetic diversity and clonal complexity of the disease. 2 Besides thrombosis, transformation to acute myeloid leukemia (AML) is a significant cause of death in MPN, 1 however, the genetic changes associated with post-MPN leukemic transformation are poorly understood. Although JAK2 mutations were suspected to be linked with post-MPN leukemic transformation, clinical studies have failed to show a significant association. 4, 13 Moreover, in JAK2-V617F-positive patients, the leukemic transformation frequently occurs on a JAK2-V617F-negative background suggesting the existence of JAK2-V617F-dependent and -independent pathways of transformation. 14, 15 In a recent study, a significant clustering of TET2 mutations with post-MPN leukemia was reported, however, TET2 defects were not specific for the transformation. 16 A specific link to post-MPN transformation was provided by the identification of somatic mutations in the IDH1 and IDH2 genes, 17 the former proven to be strongly associated with normal karyotype. 18 To gain further insights into the genetic basis of the transition from chronic phase MPN to post-MPN leukemia, we analyzed transformed MPN patients for chromosomal aberrations using high-resolution microarray karyotyping and examined cytogenetic defects for specific association with post-MPN leukemia.
Materials and methods
Patient cohort, cell sorting, DNA isolation, JAK2 and MPL mutation analysis A total of 315 MPN patients from Vienna and 240 from Pavia were included in this study. The study was approved by local ethics committees. Granulocytes and peripheral blood mononuclear cells were isolated using density gradient centrifugation. Blasts were separated from the peripheral blood mononuclear cell fraction by magnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany) for markers present on the leukemic blasts. Genomic DNA was isolated applying a standard protocol. Allelespecific PCR for the JAK2-V617F mutational analysis was carried out using a previously described protocol. 19 Allele-specific PCR for the MPL-W515L was performed based on the same methodology, but with the sense primer MPL515-F 5-GTT TCTTCCGAAGTCTGACCCTTTTTG-3, and the 5 0 -6-carboxyfluorescein labeled antisense primers MPL515-RG 5-GTAGTGTGCA GGAAACTGCC-3, and MPL515-RA 5-AAAGTAGTGTGCAGG AAACTGCA-3 using 62.2 1C annealing temperature.
Microarray genotyping, loss of heterozygosity and copy number analysis, sequencing genotyping based loss of heterozygosity (LOH) analysis, copy number analysis and IKZF1 exon sequencing.
Genotyping was conducted using the Genome-Wide Human SNP 6.0 arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocols. Evaluation of copy number and LOH was performed using the Genotyping Console version 3.0.2 software (Affymetrix).
Screening of patients for LOH in the IKZF1 gene locus was carried out by comparing SNP genotypes of granulocytes (clonal myeloid cells) with genotypes of buccal mucosa or T cells (control polyclonal tissue) in each patient. Only patients heterozygous in the control tissue were informative for the LOH analysis, as shown in Supplementary Figure 1 . Two SNPs (rs6421315 and rs7806674) located in the IKZF1 locus with an average heterozygosity frequency of over 0.4 were used for LOH analysis. As the two SNPs are in linkage disequilibrium (D' ¼ 0.05 in the HapMap CEU population) the overall informativity of the LOH analysis with these two markers was 71%. Genotyping for rs6421315 and rs7806674 was performed using the commercial Taqman assays C_3121415_10 and C_358427_10 (Applied Biosystems, Carlsbad, CA, USA). PCR and genotyping was conducted using the 7900HT Real-Time PCR System (Applied Biosystems) as recommended by the manufacturer. We also performed a real-time PCR-based copy number measurement using the commercially available assay Hs00805103_cn (Applied Biosystems) to validate the presence of copy number changes of IKZF1 detected by microarray and LOH analyses and to analyze samples for which no control paired tissue was available. The copy number assay was performed as recommended by the manufacturer.
Sequence analysis of the 7 coding IKZF1 exons (including 70-150 adjacent intron base pairs 5 0 and 3 0 of each exon) as well as of JAK2-exon14 was performed using the BigDye Terminator v3.1 Cycle Sequencing chemistry and the 3130xl Genetic Analyzer (Applied Biosystems). Primer sequences for PCR and sequencing are shown in Supplementary Table 1 .
Genotyping of hematopoietic progenitors
Peripheral blood mononuclear cells were isolated using standard density gradient centrifugation. Cells were plated in the H4431 methylcellulose media at a density of 10 5 cells/ml (StemCell Technologies, Vancouver, Canada). After culturing for 14 days, colony-forming units (CFUs) representing 'burst-forming units erythroid' and 'granulocytic-monocytic CFUs' were harvested and DNA was extracted as previously described. 20 Each CFU was assayed for the three clonal markers JAK2-V617F, del13q and del7p. JAK2-V617F mutational status was determined by sequence analysis of JAK2-exon14 as previously described. 4 Deletions on chromosome 13q were detected by LOH analysis using microsatellite PCR for D13S153. Deletions on 7p were detected by TaqMan LOH analysis using the commercial TaqMan assay C_3121415_10 (Applied Biosystems).
Vectors, lentiviral packaging, primary cell isolation and viral transduction Three short hairpin RNA (shRNA) constructs targeting the Ikzf1 transcript and one random oligonucleotide control, not homologous to any mouse transcripts, were designed for ligation into pLKO.2 lentiviral vector (kindly provided by Sebastian Nijman), which carries the puromycin-resistance gene and drives shRNA expression from a human U6 promoter. 21 All shRNA constructs were sequence verified after cloning. Three different constructs targeting the Ikzf1 mRNA were tested in duplicates for knockdown efficiency against the random oligonucleotide in the cytokine-dependent murine pro-B-cell line Ba/F3-EpoR (Ba/F3 cells expressing the erythropoietin receptor) as shown in Supplementary  Figure 2 . The target sequences of the constructs are listed in Supplementary Table 2 . The shRNA performing best in mimicking haploinsufficiency (mRNA knock-down to 50%) was further tested in four independent knock-down experiments in murine lineage marker negative (lin -) mouse bone marrow cells (Figure 4a ) and consequently used for the functional experiments. TaqMan Gene expression assays Mm01187878_m1 for Ikzf1 and Mm01545399_m1 for Hprt1 as reference were used for determination of knock-down efficiency (Applied Biosystems). Viral packaging and preparation of viral supernatant was performed in HEK293T cells as described elsewhere. 21, 22 For primary cell culture, bone marrow was isolated from tibia and femurs of C57BL/6 mice. After red blood cell lysis, bone marrow cells were cultured in StemPro-34 serum-free medium with nutrient supplement (Invitrogen, Carlsbad, CA, USA) supplied with each 10 ng/ml recombinant stem cell factor, FMS-like tyrosine kinase 3 ligand (Flt3-L), granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3 and IL-6 (R&D Systems, Minneapolis, MN, USA). The cells were depleted for adherent cells by incubation for 24 h at a density of 10 6 cells/ ml, followed by magnetic sorting of progenitor cells using the lineage cell depletion kit (CD2, CD3, CD11b, CD14, CD15, CD16, CD19, CD56, CD123 and CD235a) (Miltenyi Biotec). Fluorescence-activated cell sorting analysis after lineage cell depletion consistently showed a composition of 2% Sca1 þ cKit-, 35% Sca1 þ cKit þ , 60% Sca1-cKit þ and 3% Sca1-cKit-cells (data not shown). Viral supernatant was applied on lin -mouse bone marrow cells for 20 h in a volume ratio of 1:1 with supplemented media. Viral transduction was followed by selection on puromycin (2.5 mg/ml) for 4 days.
Proliferation assay and intracellular pStat5 and Stat5 mRNA assays
Lentivirally transduced cells with shRNA constructs targeting the Ikzf1 transcript and a random oligonucleotide control were assayed for proliferation capacity using a colorimetric assay. Cell densities of 2500 and 5000 cells per well were plated in triplicates in a 96-well plates on a dilution series of the cytokine mix (50 to 0 ng/ml each) of mouse stem cell factor, Flt3-L, granulocytemacrophage colony-stimulating factor, IL-3 and IL-6 (R&D Systems). Proliferation was determined using the Cell Proliferation Kit II XTT (Roche, Basel, Switzerland) on days 5 and 4 after plating for the plating densities 2500 and 5000, respectively.
For measurement of pStat5 induction, lentivirally transduced, puromycin selected lin -mouse bone marrow cells were starved in StemPro-34 serum-free medium with nutrient supplement (Invitrogen) for 20 h. Starved cells were counted and aliquots of 1.5 Â 10 5 cells were used for subsequent experimental processing. Both Ikzf1 knock-down and control cells were incubated with three different concentrations of IL-3 (0 ng/ml baseline, 0.025 ng/ml, 0.05 ng/ml) for 10 min at 37 1C. Phosphorylated Stat5 (pStat5) level was determined using the BD Phosflow reagents (BD Biosciences, San Jose, CA, USA). After the IL-3 incubation, cells were processed in Fix Buffer I, Perm Buffer III and Stain Buffer according to the manufacturer's protocols (BD Biosciences). Intracellular pStat5 was stained using 10 ml of the PE Mouse Anti-Stat5 (pY694) antibody in 100 ml total cell suspension for 2 h, followed by two washing steps and subsequent fluorescence-activated cell sorting analysis on a FACSCalibur instrument using the BD CellQuest software (BD Biosciences). An aliquot of IL-3-stimulated cells was processed for RNA isolation and Stat5 mRNA level was determined using
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Results

High-resolution genomic analysis of patients with post-MPN leukemia
Of the 315 Viennese MPN patients included in this study, 9 patients were diagnosed with post-MPN leukemic transformation. To gain insight into the genetic changes that precede this event, we studied these nine transformed MPN patients using high-resolution SNP microarrays. As leukemic blasts show a high degree of genomic instability resulting in extremely complex karyotypes, we focused the analysis on terminally differentiated clonal myeloid cells from these patients. Granulocyte DNA samples taken either at the time or before leukemic transformation were used for genotyping. LOH and copy number aberrations were scored in all patients to reveal chromosomal gains, losses and uniparental disomies. Acquired genetic lesions were detected in seven of the nine patients (Table 1) . We detected two cases of chromosome 7p deletions (patients 444, 455), two different chromosome 13q deletions (patients 203, 444) and several other non-recurrent lesions (Table 1) . A majority of the detected deletions spanned large genomic regions except for the common deleted region on chromosome 7p (del7p). The combined deleted region on chromosome 7p assembled from two deletion events was 0.36 Mb in size and included the IKZF1 and the FIGNL1 genes encoding the transcription factor Ikaros and the Fidgetin-like 1 protein, respectively.
Frequency of del7p in MPN and mapping of the common deleted region
To determine the frequency of IKZF1 deletions in chronic phase MPN patients, we developed screening assays based on LOH and copy number measurements by quantitative PCR (Figure 1a and Supplementary Figure 1) . Of 306 chronic phase MPN patients analyzed, 217 patients were informative for at least one of the LOH assays. One patient (117) with a diagnosis of PMF showed LOH for SNP1 but was uninformative for SNP2 (Figure 1b) . In the entire MPN patient cohort from Vienna (n ¼ 315; chronic phase MPN and post-MPN leukemia) informative for del7p analysis (n ¼ 226), del7p was present in three patients (1.3%). To test the del7p frequency in an independent patient cohort, we analyzed additional 240 MPN patients from Pavia. Twenty of these patients had post-MPN leukemia and 220 were in the chronic phase of MPN. A copy number assay mapping to exon 6 ( Figure 1a) was preferred for del7p analysis in the Pavia cohort because paired DNA samples (control tissue and myeloid cells) were available only for the 20 post-MPN leukemia patients. The analysis of IKZF1 copy number revealed three patients (Pav5, Pav11 and Pav19) with del7p in post-MPN leukemia and none in the chronic phase MPN cohort (Figure 1c) . LOH analysis using paired control and myeloid DNA samples was performed only in the post-MPN leukemic patients. In addition to Pav19, patient Pav3 tested positive for LOH with the SNP1 assay (Figure 1d) . Interestingly, patient Pav3 showed a copy number of 2 using the exon 6 assay indicating that an intragenic deletion of IKZF1 is likely in this patient with a centromeric deletion breakpoint between intron 0 and exon 6. To map the common deleted region, all patients with a detectable del7p were genotyped by microarray analysis (117, 444, 455, Pav3, Pav5, Pav11 and Pav19). One patient (117) had a 1.55 Mb deletion spanning across the IKZF1 locus and two patients (Pav11, Pav19) showed monosomy 7 ( Figure 2a) . In patients Pav3 and Pav5, the microarrays did not provide sufficient resolution to detect a microdeletion by decreased probe signal intensity, but a stretch of homozygosity within the IKZF1 gene was detected consistent with the presence of LOH in these patients (Figure 2b ). Combining the data from all patients, the common deleted region contained only the IKZF1 gene (Figure 2c ).
Clinical phenotype of del7p patients
The distribution of del7p events in the Viennese chronic MPN and post-MPN leukemia patients showed a significant Deletions of Ikaros in MPN R Jäger et al association (P ¼ 0.004) of del7p with leukemic transformation (Table 2) . Similarly, the association was present in the Pavia cohort (Table 2 ). In summary, the association of del7p (and monosomy 7) with leukemic transformation was highly significant in all the cohorts analyzed ( Table 2 ). The clinical phenotype of all del7p patients is summarized in Table 3 . Six of the seven patients with del7p transformed to AML. Patient 117 did not transform, however, the patient showed features of Only heterozygous patients for SNP1 and SNP2 in the control tissue (C) were included in the analysis. Two patients (Pav19 and Pav3) showed significant deviation from allelic ratio of 0 (log 2 ) in the granulocyte DNA (GRA) consistent with LOH for the SNP2 assay. (e) IKZF1 deletion analysis in leukemic blasts. Sorted leukemic blasts were analyzed in three patients (444, Pav19 and Pav11) carrying a chromosome 7p deletion or monosomy 7 in granulocytes (GRA). In all three patients, the IKZF1 copy number analysis revealed presence of IKZF1 deletions also in the leukemic blasts (BLASTS). The CN1 copy number assay was used for the analysis. The copy number of healthy controls (n ¼ 8) is shown for comparison (C).
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advanced phase PMF with pancytopenia and increased blasts in the peripheral blood. The mean age of del7p patients at MPN diagnosis was 56.4 years (range 39-75). In del7p patients with AML, the mean time between MPN diagnosis and leukemia was 7.7 years (range 0.3-17.6). The common clinical features of the del7p patients included anemia, thrombocytopenia and increased percentage of blasts in peripheral blood. All of the patients with post-MPN leukemia tested positive for the JAK2-V617F mutation whereas patient 117 was positive for MPL-W515L.
Leukemic blasts carry del7p and JAK2-V617F
To determine whether IKZF1 loss predisposes patients to leukemic transformation, we tested if the leukemic blasts originated from progenitors carrying the IKZF1 defect. We used DNA available from sorted leukemic blasts from three patients (444, Pav19 and Pav11) and determined the copy number of IKZF1 by quantitative PCR (Figure 1e) . In all these patients, the blasts carried the del7p or monosomy 7. In all three patients, the leukemic blasts also tested positive for the JAK2-V617F mutation by allele-specific PCR (data not shown).
Deletion of chromosome 7p is a late genetic event in MPN
In three patients with del7p (444, 117 and Pav5), DNA samples at an earlier sampling date were available for deletion analysis. None of these samples tested positive for del7p indicating that loss of IKZF1 is a genetic event acquired late in the disease progression (data not shown). To further analyze the hierarchy of genetic defects in progenitor cells, we examined CFUs in patient 444 from whom we had peripheral blood cells. In two serial samples (before and at transformation) we genotyped CFUs for del7p, JAK2-V617F and del13q. In the sample before transformation, the majority of colonies did not carry any of those defects, but a JAK2-V617F-positive clone was already present (Figure 3 ). In the later sample drawn at leukemic transformation, all 'burst-forming units erythroid' and 'granulocytic-monocytic CFU' colonies were positive for JAK2-V617F, most of them also carrying del13q. Del7p was acquired on JAK2-V617F -del13q double-positive background, resulting in a triple-positive subclone ( Figure 3) . Therefore, the order of acquisition of aberrations in patient 444 was JAK2-V617F followed by del13q and finally del7p. 
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Absence of IKZF1 point mutations in del7p and MPN patients
To distinguish between two mechanisms of tumor-suppressor inactivation (complete loss of function or haploinsufficiency), we performed sequence analysis of the seven coding IKZF1 exons and exon-intron junctions in all patients with del7p. No mutations were found on the undeleted allele of IKZF1 in these patients. In patient 117 for whom total granulocyte RNA was available for expression analysis, we detected IKZF1 mRNA expression from the remaining IKZF1 allele (data not shown). Thus, haploinsufficiency is the most likely genetic mechanism affecting IKZF1 in del7p patients. To examine the possibility that IKZF1 haploinsufficiency can occur by point mutations rather than deletions, we sequenced the IKZF1 exons in all the remaining post-MPN leukemia patients (n ¼ 23) and 73 chronic phase MPN patients but none of these carried IKZF1 point mutations (data not shown).
Loss of Ikaros increases cytokine sensitivity of primary progenitor cells
The functional consequences after complete loss of Ikaros as well as expression of the Ik6 dominant-negative isoform have been studied extensively in both cell lines and mouse models. [23] [24] [25] [26] The use of RNA interference offers a unique opportunity to model somatic monoallelic gene losses. To analyze the functional effect of IKZF1 haploinsufficiency on clonal expansion, we mimicked the defect in mouse primary progenitor cells using an shRNA-based knock-down approach. Lineage marker negative (lin -) hematopoietic progenitors stably transduced with a control construct or an shRNA construct proven to reduce Ikzf1 mRNA to approximately 50% (Figure 4a and Supplementary Figure 2) were assayed for proliferation capacity in the presence of increasing cytokine concentrations. 
Abbreviations: AML, acute myeloid leukemia; BMT, bone marrow transplantation; ET, essential thrombocythemia; F, female; HU, hydroxyurea; IFN, interferon alpha; LENAL, lenalidomide; LEU, leukemia; M, male; MPN, myeloproliferative neoplasm; NA, not applicable; PB, peripheral blood; PMF, primary myelofibrosis; PIPO, pipobroman; PV, polycythemia vera; SPL, splenomegaly; UPN, unique patient number. 
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We reproducibly observed that cells deficient for Ikaros showed increased cytokine sensitivity, but did not acquire cytokineindependent growth (Figure 4b ).
Ikaros haploinsufficiency increases Stat5 phosphorylation in primary mouse progenitor cells
As overexpression of the Ik6 dominant-negative isoform in cell lines was shown to activate the Janus Kinase-Signal Transducers and Activators of Transcription (JAK-STAT) pathway, 26 we examined the intracellular pStat5 level in the lin -bone marrow cells. Owing to cell number limitations, we used fluorescenceactivated cell sorting analysis of intracellular pStat5 staining with a monoclonal antibody specific for pStat5 (Figure 4c ). After starvation of cells transduced with either the Ikzf1 or control shRNA constructs stimulation with IL-3 resulted in a statistically significant increase in pStat5 level (Figures 4c-d ). Opposed to the pStat5 level, the total Stat5 mRNA level measured by quantitative PCR did not differ between Ikaros knock-down and control primary cells (Figure 4d ).
Discussion
We have studied the clonal genetic alterations in MPN at the time of leukemic transformation in a small cohort of patients Figure 4 Functional effects of Ikzf1 knock-down in mouse primary progenitor cells. (a) A shRNA construct effectively reduces Ikzf1 mRNA level in murine lineage marker negative bone marrow primary cells. Ikzf1 mRNA expression was determined by real-time PCR and was normalized with the expression level of Hprt1 mRNA. The shRNA construct directed against Ikzf1 (Ikzf1 shRNA) was compared with a random sequence shRNA control (control shRNA) in four independent experiments. The lentiviral shRNA construct shows a knock-down efficiency of approximately 50% compared with the control shRNA (b) Proliferation of mouse lineage marker negative bone marrow cells transduced with either the Ikzf1 shRNA (Ikzf1 shRNA) or the control random sequence shRNA construct (control shRNA). Cell growth was assayed in the presence of increasing cytokine concentrations. As cell density is crucial for proliferation and survival of primary progenitors, the assay was plated at two different densities, 2500 and 5000 cells per well, followed by the readout on experimental day 5 and 4, respectively. The mean ( ± s.d.) of optical density at 450 nm (OD450) of triplicate results is shown (error bars are hidden behind the symbols in some cases). Statistical analysis applying two-way analysis of variance (ANOVA) revealed a significant difference between control and Ikzf1 knock-down for both plating densities (****Po0.0001). Bonferroni posttest revealed that significant differences are restricted to medium cytokine concentrations (0.02-10 ng/ml), not being present at baseline and plateau. (c) Cell sorting analysis of intracellular Stat5 phosphorylation (pStat5) after IL-3 stimulation in control (control shRNA) and Ikzf1 knockdown (Ikzf1 shRNA) mouse lineage marker negative bone marrow primary cells. Baseline fluorescence is depicted by unstained controls. The graph is representative for experiments performed for three concentrations of IL-3 in each five replicates. (d) Stat5 phosphorylation and total Stat5 abundance in murine lineage marker negative bone marrow primary cells after starvation. Mean ( ± s.d.) of five replicates are shown for baseline phosphorylation (0 ng/l IL-3) and induction with 0.025 ng/ml and 0.5 ng/ml IL-3. Significance of observed differences in Stat5 phosphorylation between Control (Control shRNA) and Ikzf1 knock-down (Ikzf1 shRNA) cells was determined using unpaired t-test (*P o0.05, **Po0.01). Total Stat5 mRNA levels were determined by quantitative PCR in control (control shRNA) and Ikzf1 knock-down (Ikzf1 shRNA) murine lineage marker negative bone marrow primary cells after treatment with 0 ng/ml (baseline), 0.025 ng/ml and 0.5 ng/ml IL-3. Stat5 mRNA expression was normalized with the expression level of Hprt1 mRNA. Statistical analysis using unpaired t-test did not reveal any significant differences between the control and Ikzf1 knock-down on total Stat5 mRNA level at any IL-3 concentration.
Deletions of Ikaros in MPNusing high-resolution SNP arrays. Chromosome 7p deletions emerged as a novel recurrent defect and by mapping the common deleted region we identified the IKZF1 gene as the target of these deletions. Further examination of the frequency of IKZF1 deletions in chronic phase MPN revealed a significant association of IKZF1 deletions with leukemic transformation, which was replicated in an independent MPN patient cohort. In summary, hemizygous loss of IKZF1 (including monosomy 7) was detected in 21% of post-MPN leukemia and 0.2% of nonleukemic MPN patients.
The transcription factor Ikaros encoded by the IKZF1 gene has a pleiotropic function in the regulation of hematopoiesis. 27 Complete or partial deficiency of Ikaros function in mice induced multiple hematopoietic defects including lymphoproliferative disorders and B-and T-cell leukemia. [23] [24] [25] 28 Multiple defects were also observed in the myeloid lineages, such as anemia and thrombocythemia. 29 These functional studies in mouse models strongly suggest that decreased Ikaros function is oncogenic. In accordance with the mouse phenotypes, defects in the IKZF1 gene have been observed at high frequencies in human B-and T-cell malignancies. Most recently, IKZF1 deletions were found in approximately 84% of BCR-ABLpositive acute lymphoid leukemia (ALL). 30 Deletions of various sizes were detected on chromosome 7p including frequent intragenic deletions of IKZF1 between exons 3 and 6 responsible for the expression of the Ikaros Ik6 isoform. 30 In our study, we observed intragenic deletions in two cases but none of these was predicted to produce the Ik6 isoform. In the vast majority of ALL cases, only hemizygous deletions of IKZF1 were found, similar to our findings in MPN. Although point mutations of IKZF1 were detected in a few cases of chronic myeloid leukemia in lymphoblastoid crisis, their frequency was reported to be low. 30 ,31 Accordingly, we did not detect any sequence alterations of IKZF1 in post-MPN leukemia with or without IKZF1 deletions.
Monosomy 7 is a valuable prognostic marker in AML, and chromosome 7 defects are prominent cytogenetic lesions in PMF, associated with unfavorable prognosis and present at increasing frequency after leukemic transformation. 32, 33 Similarly, IKZF1 deletions are associated with a very poor outcome and high relapse rate in B-cell ALL. 34, 35 Monosomy 7 is known as a recurrent cytogenetic aberration in approximately 10% of adult and 5% of childhood AML cases. 36 Of the seven patients in our study showing loss of IKZF1, two had monosomy 7. This result suggests that IKZF1 may represent an important tumor-suppressor gene affected by monosomy 7.
It is still unclear how exactly Ikaros haploinsufficiency promotes the development of myeloid leukemia in MPN. We found that the IKZF1 deletion was acquired as a late event in the clonal evolution of myeloid progenitors, occurring after the acquisition of JAK2-V617F and del13q. Owing to the strong association of the IKZF1 deletion with the transformation event, it is likely that after deletion of IKZF1, myeloid progenitors acquire an increased susceptibility for transformation. This may occur because of increased chromosomal instability as all MPN patients with IKZF1 deletions showed multiple cytogenetic defects (Table 1) . Another possible mechanism is the involvement of Ikaros in the JAK-STAT signaling pathway. Mutations of Jak2 that lead to dramatic increase in its kinase activity (such as JAK2 fusions, JAK2-T875N and JAK2-R683) have been directly implicated in leukemogenesis. [37] [38] [39] [40] [41] The possible interaction of Ikaros with the JAK-STAT pathway in leukemic transformation is underlined by recent findings in childhood ALL, where JAK mutations (in particular JAK2 mutations) were significantly associated with IKZF1 defects. 42 We could induce cytokine hypersensitivity of mouse primary progenitors with shRNAmediated Ikzf1 deficiency, associated with elevated pStat5 levels ( Figure 4 ). There exists both JAK2-V617F-dependent and -independent pathways of leukemogenesis in MPN because leukemic cells are often JAK2-V617F-negative in otherwise JAK2-V617F-positive patients. 14, 15 Ikaros deficiency might contribute to JAK2-V617F-dependent leukemogenesis by further increasing the activity of the JAK-STAT pathway.
Although deletions targeting IKZF1 were shown to be present at high frequencies in ALL, these defects have not yet been observed in de novo AML, 31 or in other myeloid disorders. Our results show that deletions of IKZF1 occur in 21% of post-MPN AML patients. Thus, Ikaros has an important role not only in lymphoid malignancies but also in myeloid leukemogenesis especially if preceded by MPN.
